OpenAlex
PricingAboutJobs
Log inGet started
Work

Failure of early interval debulking surgery after standard neoadjuvant chemotherapy: May bevacizumab add something? A large retrospective study

HTML

Year: 2025
Type: article
Study design: Observational Study
Source: European Journal of Surgical Oncology
DOI: 10.1016/j.ejso.2025.110016
Authors: Raffaella Ergasti, Laura Vertechy, Ilary Ruscito, Serena Maria Boccia, Luigi Congedo, Carolina Maria Sassu, Filippo Maria Capomacchia, Barbara Costantini, Maria Grazia Distefano, Giovanni Scambia, Anna Fagotti, Claudia Marchetti
Institutions: Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore
Language: English

Topic: Ovarian cancer diagnosis and treatment
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: bevacizumab, high-grade serous ovarian cancer, neoadjuvant chemotherapy, cytoreduction, unresectable disease, overall survival, progression-free survival, postoperative complications, anti-VEGF therapy, platinum-based chemotherapy, PARP inhibitors, bevacizumab resistance
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W4409199680
FWCI:
Cites: 28
Cited by:
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security